Glaukos Corp. reported an insider sale by Senior Vice President and Chief Financial Officer Alex R. Thurman, who disposed of 2,511 shares of common stock on March 25, 2026, at $106.46 per share. The transaction generated $267,321 in proceeds and was executed while the share price was trading near $103, a level described as roughly 29% higher than six months earlier.
The disposition was disclosed in a Form 4 filing with the Securities and Exchange Commission and was carried out under a pre-arranged Rule 10b5-1 trading plan that Thurman adopted on December 15, 2025. Following the sale, Thurman directly holds 41,967 shares. That total includes 5,230 restricted stock units that have not yet vested.
The same filing also records several acquisitions attributed to Thurman on March 25, 2026. These include 3,303 shares of common stock with a recorded value of $0, together with option grants described as 8,228 Stock Options (Right to Buy) at a price of $0, 19,601 Stock Options (Right to Buy) at a price of $0, and 20,515 Stock Options (Right to Buy) at a price of $0.
Company financial posture and valuation
Glaukos is described in the filing as a medical device company with a market valuation of $6.25 billion. The company remains unprofitable, and, according to InvestingPro analysis cited in the reporting, analysts are not forecasting profitability this year. That analysis also indicates the stock is trading above its Fair Value estimate.
Regulatory and commercial developments
Separately from the insider transaction, Glaukos announced that the U.S. Food and Drug Administration has approved an NDA labeling supplement allowing for the re-administration of iDose TR using a repeat treatment protocol. The approval permits physicians to administer iDose TR more than once, effectively broadening the product's treatment options for glaucoma patients.
Analyst reactions and guidance context
Following the company's fourth-quarter 2025 revenue preannouncement and the reaffirmation of its 2026 revenue guidance, several research firms updated or maintained their assessments.
- Needham raised its price target for Glaukos to $127 and kept a Buy rating.
- Stifel reiterated a Buy rating with a $160 price target, noting a favorable risk-reward profile for the iDose product while explicitly acknowledging potential Local Coverage Determination restrictions.
- Piper Sandler maintained an Overweight rating and a $165 price target, citing multiple pathways for Glaukos to exceed consensus iDose revenue estimates for fiscal 2026.
- Stifel additionally highlighted positive developments for both iDose and Epioxa and expects sequential growth for iDose beginning in the first quarter of 2026.
What this combination of activity signifies
The insider sale, regulatory progress on iDose TR, and the cluster of supportive analyst notes together paint a picture of active corporate and market dynamics around Glaukos. The company is advancing product labeling that could affect clinical use patterns while maintaining revenue guidance that has prompted some analysts to increase their price targets. At the same time, third-party analysis flags ongoing unprofitability and a valuation above Fair Value, leaving the company positioned between commercial momentum and financial performance questions.
Summary of key developments
- CFO Alex R. Thurman sold 2,511 shares on March 25, 2026, for $267,321, under a Rule 10b5-1 plan adopted December 15, 2025.
- FDA approved an NDA labeling supplement enabling repeat administration of iDose TR.
- Analysts from Needham, Stifel, and Piper Sandler maintained or raised bullish price targets and ratings, even as InvestingPro reports the stock as overvalued and the company as unprofitable for the current year.
These items collectively highlight both near-term commercial catalysts and ongoing financial and valuation considerations for investors and market observers.